Literature DB >> 21434863

Non-alcoholic fatty liver disease in HIV infection associated with altered hepatic fatty acid composition.

Bianca M Arendt1, Saira S Mohammed, David W L Ma, Elaheh Aghdassi, Irving E Salit, David K H Wong, Maha Guindi, Morris Sherman, E Jenny Heathcote, Johane P Allard.   

Abstract

Hepatic fatty acid (FA) composition, especially a reduction in n-3 polyunsaturated FA (PUFA) may contribute to the pathogenesis of non-alcoholic fatty liver disease (NAFLD), which is common in HIV-infection.. In a cross-sectional study we compared hepatic FA composition between 20 HIV-infected men with NAFLD (HIV/NAFLD), 21 HIV-negative men with NAFLD (NAFLD), and 7 healthy controls. Within HIV/NAFLD we compared simple steatosis (HIV/SS) to steatohepatitis (HIV/NASH). FA composition in liver and erythrocytes, oxidative stress, diet, and exercise were assessed. Major findings (P<0.05) were: 1) higher hepatic n-6/n-3 ratio in HIV/NAFLD [median (range)] [8.08 (1.08-21.52)] compared to controls [5.83 (3.58-6.93)] and NAFLD [5.97 (1.46-10.40)], with higher n-6 PUFA in HIV/NAFLD compared to NAFLD; 2) lower n-3 PUFA in erythrocytes (mol%), a marker for dietary intake, in HIV/NAFLD [5.26 (1.04-11.75)] compared to controls [8.92 (4.79-12.67)]; 3) the ratios of long-chain PUFA products to essential FA precursors of the n-6 and n-3 series were lower in HIV/NAFLD and NAFLD compared to controls. In contrast, the ratio of oleic/stearic acid was higher in HIV/NAFLD compared to the other groups. These ratios are indirect markers of enzymatic FA desaturation and elongation. Hepatic PUFA, especially biologically active long-chain PUFA, were also lower in HIV/NASH compared to HIV/SS. Oxidative stress was not different among the groups. We conclude that HIV/NAFLD is associated with altered hepatic FA composition. Changes may be due to impaired FA metabolism or suboptimal n-3 PUFA intake. The potential role of n-3 PUFA (e.g. fish oil) to treat or prevent HIV/NAFLD warrants further investigation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21434863     DOI: 10.2174/157016211795569140

Source DB:  PubMed          Journal:  Curr HIV Res        ISSN: 1570-162X            Impact factor:   1.581


  6 in total

Review 1.  Metabolic clinic for individuals with HIV/AIDS: a commitment and vision to the future of HIV services.

Authors:  Mohamed H Ahmed; Clare Woodward; Dushyant Mital
Journal:  Cardiovasc Endocrinol       Date:  2017-08-18

2.  Altered lipid concentrations of liver, heart and plasma but not brain in HIV-1 transgenic rats.

Authors:  Ameer Y Taha; Mireille Basselin; Epolia Ramadan; Hiren R Modi; Stanley I Rapoport; Yewon Cheon
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2012-08-29       Impact factor: 4.006

Review 3.  Managing dyslipidemia in HIV/AIDS patients: challenges and solutions.

Authors:  Nazik Elmalaika Os Husain; Mohamed H Ahmed
Journal:  HIV AIDS (Auckl)       Date:  2014-12-17

4.  Butyrylcholinesterase Levels on Admission Predict Severity and 12-Month Mortality in Hospitalized AIDS Patients.

Authors:  Lijun Xu; Biao Zhu; Ying Huang; Zongxing Yang; Jia Sun; Yan Xu; Jinlei Zheng; Sabine Kinloch; Michael T Yin; Honglei Weng; Nanping Wu
Journal:  Mediators Inflamm       Date:  2018-03-15       Impact factor: 4.711

5.  Plasma phospholipids and fatty acid composition differ between liver biopsy-proven nonalcoholic fatty liver disease and healthy subjects.

Authors:  D W L Ma; B M Arendt; L M Hillyer; S K Fung; I McGilvray; M Guindi; J P Allard
Journal:  Nutr Diabetes       Date:  2016-07-18       Impact factor: 5.097

6.  Fatty Acid Desaturase 1 Influences Hepatic Lipid Homeostasis by Modulating the PPARα-FGF21 Axis.

Authors:  Shaminie Athinarayanan; Yang-Yi Fan; Xiaokun Wang; Evelyn Callaway; Defeng Cai; Naga Chalasani; Robert S Chapkin; Wanqing Liu
Journal:  Hepatol Commun       Date:  2020-12-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.